These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4027137)

  • 1. Caffeine disposition in obesity.
    Abernethy DR; Todd EL; Schwartz JB
    Br J Clin Pharmacol; 1985 Jul; 20(1):61-6. PubMed ID: 4027137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity effects on nitrazepam disposition.
    Abernethy DR; Greenblatt DJ; Locniskar A; Ochs HR; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1986 Nov; 22(5):551-7. PubMed ID: 3790401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digoxin disposition in obesity: clinical pharmacokinetic investigation.
    Abernethy DR; Greenblatt DJ; Smith TW
    Am Heart J; 1981 Oct; 102(4):740-4. PubMed ID: 7282520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeine pharmacokinetics in obesity and following significant weight reduction.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Int J Obes Relat Metab Disord; 1995 Apr; 19(4):234-9. PubMed ID: 7627246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cimetidine disposition in obesity.
    Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
    Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lidocaine disposition in obesity.
    Abernethy DR; Greenblatt DJ
    Am J Cardiol; 1984 Apr; 53(8):1183-6. PubMed ID: 6702701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibuprofen disposition in obese individuals.
    Abernethy DR; Greenblatt DJ
    Arthritis Rheum; 1985 Oct; 28(10):1117-21. PubMed ID: 4052122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theophylline disposition in obesity.
    Gal P; Jusko WJ; Yurchak AM; Franklin BA
    Clin Pharmacol Ther; 1978 Apr; 23(4):438-44. PubMed ID: 630791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Eur J Clin Pharmacol; 1995; 47(6):525-30. PubMed ID: 7768256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbamazepine pharmacokinetics in obese and lean subjects.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Ann Pharmacother; 1995 Sep; 29(9):843-7. PubMed ID: 8547729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin disposition in obesity. Determination of loading dose.
    Abernethy DR; Greenblatt DJ
    Arch Neurol; 1985 May; 42(5):468-71. PubMed ID: 3994563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of quinine in obesity.
    Viriyayudhakorn S; Thitiarchakul S; Nachaisit S; Ho PC; Wanwimolruk S
    Trans R Soc Trop Med Hyg; 2000; 94(4):425-8. PubMed ID: 11127249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
    Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM
    Cancer Chemother Pharmacol; 1989; 25(2):139-42. PubMed ID: 2557169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisolone disposition in obese men.
    Milsap RL; Plaisance KI; Jusko WJ
    Clin Pharmacol Ther; 1984 Dec; 36(6):824-31. PubMed ID: 6499362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives.
    Abernethy DR; Todd EL
    Eur J Clin Pharmacol; 1985; 28(4):425-8. PubMed ID: 4029248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity, sex, and acetaminophen disposition.
    Abernethy DR; Divoll M; Greenblatt DJ; Ameer B
    Clin Pharmacol Ther; 1982 Jun; 31(6):783-90. PubMed ID: 7075126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procainamide disposition in obesity.
    Christoff PB; Conti DR; Naylor C; Jusko WJ
    Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of sufentanil in obese patients.
    Schwartz AE; Matteo RS; Ornstein E; Young WL; Myers KJ
    Anesth Analg; 1991 Dec; 73(6):790-3. PubMed ID: 1835321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers.
    Kamimori GH; Somani SM; Knowlton RG; Perkins RM
    Eur J Clin Pharmacol; 1987; 31(5):595-600. PubMed ID: 3830245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.
    Abernethy DR; Greenblatt DJ; Divoll M; Smith RB; Shader RI
    Clin Pharmacokinet; 1984; 9(2):177-83. PubMed ID: 6143633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.